Abstract LB135: Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1/4-1BB bispecific compound for tumor localized activation of the immune system
Abstract Background. Preclinical and clinical data suggest that 4-1BB (CD137), a costimulatory immunoreceptor mainly expressed by cytotoxic cells, represents a promising therapeutic target in cancer. A combination of checkpoint blockade with further T-cell activation mediated by 4-1BB co-stimulation...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 81; no. 13_Supplement; p. LB135 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.07.2021
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Background. Preclinical and clinical data suggest that 4-1BB (CD137), a costimulatory immunoreceptor mainly expressed by cytotoxic cells, represents a promising therapeutic target in cancer. A combination of checkpoint blockade with further T-cell activation mediated by 4-1BB co-stimulation may increase response rates and durability of response. However, the efficacy of systemic 4-1BB stimulation is limited by on target peripheral toxicity events. PRS-344/S095012 has been designed to provide the potential of a combinatorial therapy in one molecule and favor the localized stimulation of antigen-specific T cells in the tumor microenvironment, potentially reducing peripheral toxicity. Methods. Anticalin® proteins are 18 kDa protein therapeutics derived from human lipocalins. We utilized phage display technologies to generate an Anticalin protein that binds to 4-1BB with high affinity and specificity. PRS-344/S095012 was generated by recombinant fusion of two 4-1BB-specific Anticalin proteins to a PD-L1-targeting monoclonal antibody with a modified IgG4 backbone that avoids interaction with Fc gamma receptors and restricts 4-1BB agonism to PD-L1 positive tissues. The activity and potency of PRS-344/S095012 were investigated in binding assays, functional in vitro assays with human primary immune cells, as well as in a human 4-1BB knock in mouse model. Results. The bispecific fusion protein PRS-344/S095012 is capable of binding 4-1BB and PD-L1 simultaneously. We show that the bispecific compound retains its ability to block PD-1/PD-L1 receptor-ligand interaction with similar potency to the parental PD-L1 antibody. In relevant in vitro cell-based assays, PRS-344/S095012 enhances T cell effector functions only in the presence of PD-L1 positive cells, in line with the desired mechanism of action. In vitro, we show that PRS-344/S095012 activity is superior to PD-L1 antibodies, and to the combination of clinically relevant 4-1BB and PD-L1 benchmark antibodies. In a human 4-1BB knock in mouse model, subcutaneously implanted with a human PD-L1 expressing tumor, PRS-344/S095012 showed clear superiority to anti-PD-L1 alone and a robust antitumor response that leads to the complete regression of implanted tumors and extension of survival. Conclusion. We report potent costimulatory T cell engagement of the immunoreceptor 4-1BB in a PD-L1-dependent manner, utilizing the PD-L1/4-1BB bispecific compound PRS-344/S095012. This approach has the potential to provide a localized costimulation of the immune system with high efficacy and reduced peripheral toxicity. Furthermore, dual mechanism of action combining PD-L1-dependent 4-1BB agonist activity with simultaneous PD-1/PD-L1 pathway blockade provides an additional therapeutic benefit in preclinical models. Taken together our in vitro and in vivo data outlines proof of concept functionality of PRS-344/S095012 and supports further development of this promising compound.
Citation Format: Aizea Morales-Kastresana, Marina Pavlidou, Janet Peper, Lucia Pattarini, Christian Barthels, Eva-Maria Hansbauer, Rachida Bel Aiba, Birgit Bossenmaier, Alix Scholer-Dahirel, Thomas Jaquin, Catherine Gallou, Véronique Blanc, Christine Rothe, Shane Olwill. Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1/4-1BB bispecific compound for tumor localized activation of the immune system [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB135. |
---|---|
AbstractList | Abstract
Background. Preclinical and clinical data suggest that 4-1BB (CD137), a costimulatory immunoreceptor mainly expressed by cytotoxic cells, represents a promising therapeutic target in cancer. A combination of checkpoint blockade with further T-cell activation mediated by 4-1BB co-stimulation may increase response rates and durability of response. However, the efficacy of systemic 4-1BB stimulation is limited by on target peripheral toxicity events. PRS-344/S095012 has been designed to provide the potential of a combinatorial therapy in one molecule and favor the localized stimulation of antigen-specific T cells in the tumor microenvironment, potentially reducing peripheral toxicity. Methods. Anticalin® proteins are 18 kDa protein therapeutics derived from human lipocalins. We utilized phage display technologies to generate an Anticalin protein that binds to 4-1BB with high affinity and specificity. PRS-344/S095012 was generated by recombinant fusion of two 4-1BB-specific Anticalin proteins to a PD-L1-targeting monoclonal antibody with a modified IgG4 backbone that avoids interaction with Fc gamma receptors and restricts 4-1BB agonism to PD-L1 positive tissues. The activity and potency of PRS-344/S095012 were investigated in binding assays, functional in vitro assays with human primary immune cells, as well as in a human 4-1BB knock in mouse model. Results. The bispecific fusion protein PRS-344/S095012 is capable of binding 4-1BB and PD-L1 simultaneously. We show that the bispecific compound retains its ability to block PD-1/PD-L1 receptor-ligand interaction with similar potency to the parental PD-L1 antibody. In relevant in vitro cell-based assays, PRS-344/S095012 enhances T cell effector functions only in the presence of PD-L1 positive cells, in line with the desired mechanism of action. In vitro, we show that PRS-344/S095012 activity is superior to PD-L1 antibodies, and to the combination of clinically relevant 4-1BB and PD-L1 benchmark antibodies. In a human 4-1BB knock in mouse model, subcutaneously implanted with a human PD-L1 expressing tumor, PRS-344/S095012 showed clear superiority to anti-PD-L1 alone and a robust antitumor response that leads to the complete regression of implanted tumors and extension of survival. Conclusion. We report potent costimulatory T cell engagement of the immunoreceptor 4-1BB in a PD-L1-dependent manner, utilizing the PD-L1/4-1BB bispecific compound PRS-344/S095012. This approach has the potential to provide a localized costimulation of the immune system with high efficacy and reduced peripheral toxicity. Furthermore, dual mechanism of action combining PD-L1-dependent 4-1BB agonist activity with simultaneous PD-1/PD-L1 pathway blockade provides an additional therapeutic benefit in preclinical models. Taken together our in vitro and in vivo data outlines proof of concept functionality of PRS-344/S095012 and supports further development of this promising compound.
Citation Format: Aizea Morales-Kastresana, Marina Pavlidou, Janet Peper, Lucia Pattarini, Christian Barthels, Eva-Maria Hansbauer, Rachida Bel Aiba, Birgit Bossenmaier, Alix Scholer-Dahirel, Thomas Jaquin, Catherine Gallou, Véronique Blanc, Christine Rothe, Shane Olwill. Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1/4-1BB bispecific compound for tumor localized activation of the immune system [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB135. |
Author | Hansbauer, Eva-Maria Jaquin, Thomas Morales-Kastresana, Aizea Pavlidou, Marina Scholer-Dahirel, Alix Gallou, Catherine Barthels, Christian Blanc, Véronique Pattarini, Lucia Rothe, Christine Bossenmaier, Birgit Aiba, Rachida Bel Peper, Janet Olwill, Shane |
Author_xml | – sequence: 1 givenname: Aizea surname: Morales-Kastresana fullname: Morales-Kastresana, Aizea – sequence: 2 givenname: Marina surname: Pavlidou fullname: Pavlidou, Marina – sequence: 3 givenname: Janet surname: Peper fullname: Peper, Janet – sequence: 4 givenname: Lucia surname: Pattarini fullname: Pattarini, Lucia – sequence: 5 givenname: Christian surname: Barthels fullname: Barthels, Christian – sequence: 6 givenname: Eva-Maria surname: Hansbauer fullname: Hansbauer, Eva-Maria – sequence: 7 givenname: Rachida Bel surname: Aiba fullname: Aiba, Rachida Bel – sequence: 8 givenname: Birgit surname: Bossenmaier fullname: Bossenmaier, Birgit – sequence: 9 givenname: Alix surname: Scholer-Dahirel fullname: Scholer-Dahirel, Alix – sequence: 10 givenname: Thomas surname: Jaquin fullname: Jaquin, Thomas – sequence: 11 givenname: Catherine surname: Gallou fullname: Gallou, Catherine – sequence: 12 givenname: Véronique surname: Blanc fullname: Blanc, Véronique – sequence: 13 givenname: Christine surname: Rothe fullname: Rothe, Christine – sequence: 14 givenname: Shane surname: Olwill fullname: Olwill, Shane |
BookMark | eNo9Udtu2zAMFYYOWJrtFwZ-QNVIthTHe0va7gJkWLF0z4ZMU41WWwosuUD2dfu0KenQFxKHBA_Jcy7ZhQ-eGPsoxbWUerWQulzxSil9vf5eiELy7UaW-g2bvTYu2EwIseJaVcU7dhnj7wy1FHrG_q7bmEaDCc5Tn2DnhqlPxlOYImCI6YRNCuMRHjhS3wP5R_NIA_kExneAe8KnQ3AZOr93rUsueGiPcP9zx0ulFjtRayGLKzBwf8u3cqG43GygdfFA6KzDvGY4hClz2TBCmoYc-4Cmd3-og3ybezZn0mAh7QncMEyeIB5jouE9e2tNH-nD_zxnvz7fPdx85dsfX77drLccZf6Vo-p0K5QloyqLaGSJXaupEFa1ZZallraolljXXS51uJQCSduKOlN1tbCynLPlCy-OIcaRbHMY3WDGYyNFc_KhOcndnORuXnxozoqW_wDru39i |
CitedBy_id | crossref_primary_10_1080_19420862_2023_2167189 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1158/1538-7445.AM2021-LB135 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-7445 |
EndPage | LB135 |
ExternalDocumentID | 10_1158_1538_7445_AM2021_LB135 |
GroupedDBID | --- -ET 18M 29B 2WC 34G 39C 476 53G 5GY 5RE 5VS 6J9 AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CITATION CS3 DIK DU5 EBS EJD F5P FRP GX1 IH2 KQ8 L7B LSO OK1 P0W P2P PQQKQ RCR RHF RHI RNS SJN TR2 W2D W8F WH7 WOQ YKV YZZ |
ID | FETCH-LOGICAL-c1005-c4d5b04fea47fcca13cdb5e20f4b347291f276c99d20fdc610ce5f7eda7d90f13 |
ISSN | 0008-5472 |
IngestDate | Thu Sep 26 17:15:07 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 13_Supplement |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1005-c4d5b04fea47fcca13cdb5e20f4b347291f276c99d20fdc610ce5f7eda7d90f13 |
ParticipantIDs | crossref_primary_10_1158_1538_7445_AM2021_LB135 |
PublicationCentury | 2000 |
PublicationDate | 2021-07-01 |
PublicationDateYYYYMMDD | 2021-07-01 |
PublicationDate_xml | – month: 07 year: 2021 text: 2021-07-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | Cancer research (Chicago, Ill.) |
PublicationYear | 2021 |
SSID | ssj0005105 |
Score | 2.4150522 |
Snippet | Abstract
Background. Preclinical and clinical data suggest that 4-1BB (CD137), a costimulatory immunoreceptor mainly expressed by cytotoxic cells, represents a... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | LB135 |
Title | Abstract LB135: Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1/4-1BB bispecific compound for tumor localized activation of the immune system |
Volume | 81 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF61RUJcEE_x1h64BSexvesHt6SAqrZBgaZSb5a9D2KRJlFxKtFfx09jZndjL1AhysVKrGT8mM87s-vvmyHkdZJwmcgoCSKpZcAymLOWFZeBwjbcKeQQlSnXNPmYHJyywzN-trM78FhLm6bqi6trdSX_41XYB35FlewNPNsahR3wGfwLW_AwbP_Jx6MKFypE0zsehzHHyf1JjQzBcqmQ2SpW8PyeY38ufJE-C3CRvqeWXxzfxUra5kp8Xa_qJbYKmNeVYXBhTjr9fBLEjJk3rTmHAGN4nr3pu-AYBz8WhONxr6pRqYlsI8NNxxZNlre4OYetiZP1FaS0qJ64bJNTzHVr1KUoV0jaz5D3EYYXPVeEaG7eMlu6iBnOFou-t3gxwfoC6ltwVBrNS2kFbiM4ZhttpuXloparjRMmuW7hNhqsLV4P4X55MvCmwZ9Z1fhG1KW_MBKFLYm2G-yzgDPbGaivuvE9ZbaC5TYAZKEP9Lgw_VQ74pEd2Y0jvTSh_f5nDOKoq2iP1B9NzNl5Bvyi378F45YiaSZnPCvQToF2CmunMHZ2ya0ozTmuNhx96srjc8fZ3V65k8SDncH15-NlY15aNbtH7rr5EB1ZcN8nO2r5gNyeOMbHQ_Jji3FqLL2lPsLpLwinFuG0QzgFhNMO4bRDOK2-U4fwgcP3G1pSg-6BwTbtsE232KaAbWqwTVts0w7bdKUpYJtabFOL7Ufk9MP72f5B4LqOBCLEsryCSV4NmVYlSzWMb2EsZMVVNNSsiuGe5qGO0kTkuYRdUsD0QyiuUyXLVOZDHcaPyd5ytVRPCA15ItIoyzXk8GyoeT7MM6EE1wJmTUrHT8lge_eLtS0uU_zd789u_I_n5E73cLwge83FRr2EPLqpXhns_ASGNMGY |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abstract+LB135%3A+Simultaneous+costimulatory+T-cell+engagement+and+checkpoint+inhibition+by+PRS-344%2FS095012%2C+a+PD-L1%2F4-1BB+bispecific+compound+for+tumor+localized+activation+of+the+immune+system&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Morales-Kastresana%2C+Aizea&rft.au=Pavlidou%2C+Marina&rft.au=Peper%2C+Janet&rft.au=Pattarini%2C+Lucia&rft.date=2021-07-01&rft.issn=0008-5472&rft.eissn=1538-7445&rft.volume=81&rft.issue=13_Supplement&rft.spage=LB135&rft.epage=LB135&rft_id=info:doi/10.1158%2F1538-7445.AM2021-LB135&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_1538_7445_AM2021_LB135 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon |